CD19-CAR-NK cells with ectopic IL-15 expression and iC9 suicide gene have gained clinical success against CD19+ lymphoma, with 7/11 recipients demonstrating complete remission, and proven safety, whereby none of the recipients developed symptoms of CRS, GvHD and neurotoxicity. Here, CD19 is linked to congenital rubella syndrome.